Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Novartis agreement to supply rhPDGF-BB to BioMimetic amended

Jan. 7, 2010

Phase II investigation of diabetes treatment EGT-0001442 begins

Jan. 7, 2010

Dr. Reddy's Laboratories and Nordic Bioscience report results from phase III balaglitazone trial

Jan. 5, 2010

Novo Nordisk initiates phase I trial of oral insulin analogue NN-1952

Jan. 5, 2010

Teijin Pharma presents cathepsin K inhibitors for osteoporosis

Jan. 4, 2010

Biodel submits NDA to FDA for VIAject for treatment of diabetes

Jan. 4, 2010

FDA review of Vytorin deems cancer risk "unlikely"

Dec. 31, 2009

Novo Nordisk provides update on timeline for formal FDA feedback on liraglutide

Dec. 31, 2009

Esteve discloses 5-HT6 receptor ligands for the treatment of eating disorders

Dec. 31, 2009

CKD Pharmaceuticals describes discovery of PDE5 inhibitor CKD-533

Dec. 31, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...